NDRA · Endra Life Sciences Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $776.4K | - | $432.1K | $381.1K | $528.7K | - | $794.4K | $716.4K | $1.04M | - |
| SG&A | $1.39M | - | $893.3K | $851.2K | $871.6K | - | $631.4K | $1.35M | $1.50M | - |
| Total Operating Expenses | $2.17M | - | $1.37M | $1.30M | $1.47M | - | $1.51M | $2.23M | $2.78M | - |
| D&A | $13.8K | - | $10.8K | - | $13.8K | - | $11.5K | - | $15.3K | - |
| Operating Income | ($2.17M) | - | ($1.37M) | ($1.30M) | ($1.47M) | - | ($1.51M) | ($2.23M) | ($2.78M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($1.31M) | - | ($1.60M) | ($1.23M) | ($1.04M) | - | ($2.35M) | ($2.23M) | ($2.78M) | - |
| EPS - Basic | ($1.09) | - | ($9.54) | - | - | - | - | - | - | - |
| EPS - Diluted | ($1.86) | - | ($9.54) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $356.5K | $762.4K | $794.0K | $1.81M | $2.06M | $3.23M | $4.75M | $6.40M | $1.13M | $2.83M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | $0 | $0 | $0 | $0 | $0 | $2.71M | $2.71M | $2.71M | $2.62M |
| Accounts Payable | $456.8K | $383.0K | $252.5K | $282.0K | $223.6K | $269.7K | $279.4K | $300.4K | $521.6K | $360.4K |
| Current Assets | $536.7K | $968.0K | $1.05M | $1.85M | $2.18M | $3.43M | $4.96M | $6.71M | $1.27M | $3.03M |
| Total Assets | $3.44M | $3.85M | $1.96M | $2.81M | $3.17M | $4.45M | $8.38M | $10.44M | $5.06M | $6.75M |
| Current Liabilities | $835.4K | $751.0K | $800.3K | $576.6K | $565.8K | $605.2K | $814.0K | $1.35M | $1.22M | $903.1K |
| Long-term Debt | - | - | - | - | - | $0 | - | - | $0 | $0 |
| Total Liabilities | $1.65M | $1.59M | $1.79M | $1.33M | $1.42M | $1.89M | $1.77M | $1.45M | $1.36M | $1.10M |
| Stockholders' Equity | $1.79M | $2.26M | $171.4K | $1.47M | $1.75M | $2.56M | $6.60M | $8.99M | $3.70M | $5.66M |
| Retained Earnings | ($111.78M) | ($110.47M) | ($107.30M) | ($105.70M) | ($104.47M) | ($103.44M) | ($99.29M) | ($96.94M) | ($94.71M) | ($91.93M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.12M) | - | - | - | ($1.29M) | - | - | - | ($2.14M) | - |
| Investing Cash Flow | $450.0K | - | - | - | ($17.3K) | - | - | - | ($23.8K) | - |
| Financing Cash Flow | $263.7K | - | - | - | $145.8K | - | - | - | $468.9K | - |
| CapEx | - | - | - | - | $17.3K | - | - | - | $27.0K | - |
| Free Cash Flow | - | - | - | - | ($1.31M) | - | - | - | ($2.17M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 1.26 | - | - | - | 0.78 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -38.1% | - | -81.3% | -43.7% | -32.7% | - | -28.1% | -21.3% | -54.8% | - |
| Return on equity | -73.4% | - | -931.2% | -83.2% | -59.1% | - | -35.6% | -24.8% | -75.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | -59.4% | - |
| Liquidity | ||||||||||
| Current ratio | 0.64 | 1.29 | 1.31 | 3.21 | 3.85 | 5.67 | 6.10 | 4.97 | 1.04 | 3.36 |
| Quick ratio | 0.64 | 1.29 | 1.31 | 3.21 | 3.85 | 5.67 | 2.76 | 2.96 | -1.18 | 0.45 |
| Cash ratio | 0.43 | 1.02 | 0.99 | 3.14 | 3.65 | 5.34 | 5.83 | 4.74 | 0.93 | 3.14 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.00 | - | - | 0.00 | 0.00 |
| Debt / Assets | - | - | - | - | - | 0.00 | - | - | 0.00 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.92 | 1.71 | 11.46 | 1.91 | 1.81 | 1.74 | 1.27 | 1.16 | 1.37 | 1.19 |
| Liabilities / Assets | 0.48 | 0.41 | 0.91 | 0.48 | 0.45 | 0.42 | 0.21 | 0.14 | 0.27 | 0.16 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.5x | - | 7.7x | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -47.9% | - | 9.2% | 41.7% | 47.2% | - | 51.8% | 25.5% | 5.4% | - |
| Net income growth (YoY) | -26.5% | - | 32.2% | 45.0% | 62.7% | - | 24.1% | 12.8% | 5.7% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 39.6% | - | - | - | 14.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1.9% | -11.7% | -97.4% | -83.6% | -52.6% | -54.8% | 27.1% | 29.8% | -17.8% | -21.5% |
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing ENDRA Life Sciences Inc. against the 5 most active filers in the same SIC group.